Needham & Company LLC Forecasts Strong Price Appreciation for Evolent Health (NYSE:EVH) Stock

Evolent Health (NYSE:EVH) had its price objective increased by Needham & Company LLC from $5.00 to $6.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the technology company’s stock. Needham & Company LLC‘s target price points to a potential upside of 31.15% from the company’s previous close.

Several other equities analysts have also commented on EVH. Canaccord Genuity Group cut their price target on Evolent Health from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Truist Financial lowered their price objective on shares of Evolent Health from $7.00 to $6.00 and set a “hold” rating for the company in a research note on Wednesday, August 12th. Weiss Ratings cut shares of Evolent Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 16th. Citigroup upgraded shares of Evolent Health from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $6.75 to $6.00 in a report on Monday, August 10th. Finally, TD Cowen raised their target price on shares of Evolent Health from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Monday, August 17th. Eleven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $6.04.

Evolent Health Trading Down 4.7%

Shares of NYSE EVH traded down $0.23 during trading hours on Thursday, reaching $4.58. The stock had a trading volume of 3,491,526 shares, compared to its average volume of 2,841,592. Evolent Health has a 52-week low of $2.10 and a 52-week high of $6.34. The firm has a market cap of $517.25 million, a price-to-earnings ratio of -1.00 and a beta of 1.03. The business’s fifty day moving average price is $4.17 and its two-hundred day moving average price is $3.88. The company has a current ratio of 1.24, a quick ratio of 1.24 and a debt-to-equity ratio of 2.52.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, November 5th. The technology company reported $0.06 EPS for the quarter, hitting the consensus estimate of $0.06. The company had revenue of $725.37 million for the quarter, compared to the consensus estimate of $727.06 million. Evolent Health had a negative return on equity of 4.27% and a negative net margin of 24.08%. Evolent Health’s quarterly revenue was up 51.3% on a year-over-year basis. During the same period last year, the business posted $0.05 EPS. Analysts expect that Evolent Health will post -0.25 EPS for the current fiscal year.

Insider Activity

In other news, President Daniel Mccarthy sold 65,892 shares of Evolent Health stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $5.00, for a total value of $329,460.00. Following the transaction, the president directly owned 655,133 shares in the company, valued at approximately $3,275,665. This trade represents a 9.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.48% of the company’s stock.

Institutional Investors Weigh In On Evolent Health

A number of hedge funds have recently made changes to their positions in EVH. Vise Technologies Inc. boosted its position in Evolent Health by 76.5% during the third quarter. Vise Technologies Inc. now owns 30,215 shares of the technology company’s stock valued at $105,000 after purchasing an additional 13,096 shares in the last quarter. State of Wyoming grew its stake in Evolent Health by 37.3% in the third quarter. State of Wyoming now owns 113,074 shares of the technology company’s stock valued at $395,000 after purchasing an additional 30,720 shares during the last quarter. Tempus Wealth Planning LLC raised its holdings in Evolent Health by 20.2% in the third quarter. Tempus Wealth Planning LLC now owns 100,774 shares of the technology company’s stock worth $352,000 after purchasing an additional 16,969 shares in the last quarter. Congress Asset Management Co. raised its holdings in Evolent Health by 20.3% in the third quarter. Congress Asset Management Co. now owns 275,158 shares of the technology company’s stock worth $960,000 after purchasing an additional 46,466 shares in the last quarter. Finally, Sequoia Financial Advisors LLC bought a new position in Evolent Health in the second quarter worth about $78,000.

Key Headlines Impacting Evolent Health

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Evolent issued FY 2026 revenue guidance of $2.6 billion to $2.7 billion. The midpoint is above analysts’ $2.6 billion consensus, and the high end suggests potential upside to expectations.
• Positive Sentiment: Q3 earnings were $0.06 per share, matching estimates and up from $0.05 a year earlier. Revenue rose 51.3% year over year to $725.37 million. CEO Seth Blackley said customers are renewing agreements and, in many cases, expanding their work with Evolent. Evolent Announces Third Quarter 2026 Results
• Negative Sentiment: Quarterly revenue was slightly below analysts’ $727.06 million estimate. The company also reported a negative net margin of 24.08%, highlighting that profitability remains a concern despite strong revenue growth.

Evolent Health Company Profile

Evolent Health, Inc (NYSE: EVH) is a healthcare services and technology company that helps health plans and healthcare providers transition to value-based care. Its platform is designed to support the management of clinical programs, improve patient outcomes and coordinate care while helping customers manage healthcare costs.

The company provides specialty and total-cost-of-care solutions across areas such as cardiology, oncology, musculoskeletal care, radiology and other complex conditions.